Patents Assigned to MAXCYTE, Inc.
-
Publication number: 20200237825Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.Type: ApplicationFiled: April 15, 2020Publication date: July 30, 2020Applicant: Maxcyte, Inc.Inventors: Linhong LI, Madhusudan V. PESHWA
-
Patent number: 10660917Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.Type: GrantFiled: May 23, 2017Date of Patent: May 26, 2020Assignee: Maxcyte, Inc.Inventors: Linhong Li, Madhusudan V. Peshwa
-
Patent number: 10316335Abstract: Methods and compositions are provided involving high producing cell lines. Embodiments concern efficient methods for screening for such cell lines and for creating such cell lines. These cell lines can be used to create large amounts of protein. To quickly generate large quantity of recombinant proteins or vaccines for both pre-clinical study and clinical trials, almost all drug development will face the same challenging obstacle of rapidly generating a high stable producer. Developing and identifying a stable cell line is a critical part of biopharmaceutical development.Type: GrantFiled: March 14, 2014Date of Patent: June 11, 2019Assignee: MaxCyte, Inc.Inventors: Weili Wang, James P. Brady, Madhusudan V. Peshwa
-
Publication number: 20180112235Abstract: Compositions and methods concern the sequence modification of an endogenous genomic DNA region. Certain aspects relate to a method for site-specific sequence modification of a target genomic DNA region in cells comprising: contacting the cells with an activating composition; transfecting the cells with a transfection composition comprising (a) donor DNA and (b) a DNA digesting agent; wherein the donor DNA comprises: (i) a homologous region comprising nucleic acid sequence homologous to the target genomic DNA region; and (ii) a sequence modification region; and wherein the genomic DNA sequence is modified specifically at the target genomic DNA region.Type: ApplicationFiled: April 13, 2016Publication date: April 26, 2018Applicant: MaxCyte, Inc.Inventors: Linhong Li, Madhusudan PESHWA
-
Publication number: 20180028567Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.Type: ApplicationFiled: October 6, 2017Publication date: February 1, 2018Applicant: Maxcyte, Inc.Inventors: Linhong LI, Madhusudan V. PESHWA
-
Publication number: 20170258837Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.Type: ApplicationFiled: May 23, 2017Publication date: September 14, 2017Applicant: Maxcyte, Inc.Inventors: Linhong LI, Madhusudan V. PESHWA
-
Patent number: 9669058Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.Type: GrantFiled: August 25, 2015Date of Patent: June 6, 2017Assignee: Maxcyte, Inc.Inventors: Linhong Li, Madhusudan V. Peshwa
-
Patent number: 9546350Abstract: The electroporation chamber and its related devices combine the features of an electroporation chamber that acts as a manifold for regulation of sample flow with those of a flow electroporation device to form a regulated flow electroporation device. The invention further comprises a novel regulated flow electroporation chamber that enables conditions in which a sample is uniformly processed in individual fractions or volumes in a fully closed (sterile) system.Type: GrantFiled: August 10, 2010Date of Patent: January 17, 2017Assignee: Maxcyte, Inc.Inventors: Sergey Dzekunov, Nicholas Chopas, Linhong Li
-
Patent number: 9132153Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.Type: GrantFiled: May 24, 2013Date of Patent: September 15, 2015Assignee: MaxCyte, Inc.Inventors: Linhong Li, Madhusudan V. Peshwa
-
Patent number: 8450112Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.Type: GrantFiled: April 9, 2009Date of Patent: May 28, 2013Assignee: Maxcyte, Inc.Inventors: Linhong Li, Madhusudan V. Peshwa
-
Publication number: 20120088842Abstract: Embodiments of the invention are directed to a technique for electroporation that allows for a delivery of long electrical pulses of high magnitude in highly conductive buffers and minimizes damage to cells undergoing electroporation.Type: ApplicationFiled: July 15, 2009Publication date: April 12, 2012Applicant: MAXCYTE, INC.Inventor: Sergey Dzekunov
-
Patent number: 7991559Abstract: Techniques for computerized electroporation. An electroporation apparatus may be controlled according to one of a plurality of previously-saved, user-defined processing protocols. A processing log associated with a processing protocol may be generated, and the processing log may include patient or sample specific information. The processing log or a summary of the processing log may be exported to a user. Interactive instructions may be provided to a user. Those instructions may correspond to one or more steps of a processing protocol.Type: GrantFiled: November 30, 2005Date of Patent: August 2, 2011Assignee: Maxcyte Inc.Inventors: Sergey M. Dzekunov, Sarah H. Wang, Arthur D. Hanson
-
Patent number: 7771984Abstract: The electroporation chamber and its related devices combine the features of an electroporation chamber that acts as a manifold for regulation of sample flow with those of a flow electroporation device to form a regulated flow electroporation device. The invention further comprises a novel regulated flow electroporation chamber that enables conditions in which a sample is uniformly processed in individual fractions or volumes in a fully closed (sterile) system.Type: GrantFiled: May 12, 2005Date of Patent: August 10, 2010Assignee: Maxcyte, Inc.Inventors: Sergey Dzekunov, Nicholas Chopas, Linhong Li
-
Patent number: 7186559Abstract: The present invention relates to methods and apparatus for the encapsulation of biologically-active substances in various cell populations. More particularly, the present invention relates to a method and apparatus for the encapsulation of biologically-active substances in various cell populations in blood by electroporation to achieve therapeutically desirable changes in the physical characteristics of the various cell populations in blood.Type: GrantFiled: January 5, 2004Date of Patent: March 6, 2007Assignee: Maxcyte, Inc.Inventors: Sergey M. Dzekunov, Linhong Li, Vininder Singh, Linda Liu, John W. Holaday, Hyung J. Lee
-
Patent number: 7141425Abstract: The present invention relates to methods and apparatus for the encapsulation of biologically-active substances in various cell populations. More particularly, the present invention relates to a method and apparatus for the encapsulation of biologically-active substances in various cell populations in blood by electroporation to achieve therapeutically desirable changes in the physical characteristics of the various cell populations in blood.Type: GrantFiled: August 21, 2002Date of Patent: November 28, 2006Assignee: Maxcyte, Inc.Inventors: Sergey M. Dzekunov, Hyung J. Lee, Linhong Li, Vininder Singh, Linda Liu, John W. Holaday
-
Patent number: 7029916Abstract: The present invention relates to methods and apparatus for the encapsulation of biologically-active substances in various cell populations. More particularly, the present invention relates to a method and apparatus for the encapsulation of biologically-active substances in various cell populations in blood by electroporation to achieve therapeutically desirable changes in the physical characteristics of the various cell populations in blood.Type: GrantFiled: February 21, 2002Date of Patent: April 18, 2006Assignee: MAXCYTE, Inc.Inventors: Sergey M. Dzekunov, Hyung J. Lee, Linhong Li, Vininder Singh, Linda Liu, John W. Holaday
-
Publication number: 20040214333Abstract: Methods for loading an antigen-presenting cell with one ore more antigens are disclosed. Methods for the treatment and prevention of a disease in a subject using an antigen-presenting cell that has been electroporated with a composition of one or more antigens. Composition of one or more antigens comprises one or more antigens of a hyperproliferative cell, a microorganism or a microorganism-infected cell are also disclosed. In addition, compositions of antigen-presenting cells that have been loaded with one or more antigens of a hyperproliferative cell, a microorganism-infected cell or a microorganism using electroporation are disclosed.Type: ApplicationFiled: February 18, 2004Publication date: October 28, 2004Applicant: MaxCyte, Inc.Inventors: Linda N. Liu, Jonathan M. Weiss
-
Publication number: 20040197883Abstract: The present invention relates to methods and apparatus for the encapsulation of biologically-active substances in various cell populations. More particularly, the present invention relates to a method and apparatus for the encapsulation of biologically-active substances in various cell populations in blood by electroporation to achieve therapeutically desirable changes in the physical characteristics of the various cell populations in blood.Type: ApplicationFiled: January 5, 2004Publication date: October 7, 2004Applicant: MAXCYTE, Inc.Inventors: Sergey M. Dzekunov, Linhong Li, Vininder Singh, Linda Liu, John W. Holaday, Hyung J. Lee
-
Patent number: 6773669Abstract: The present invention relates to a method and apparatus for the encapsulation of substances and drugs into cells and platelets. The present invention is also related to the incorporation of thrombus dissolving drugs, such as tissue plasminogen activator and streptokinase into platelets using the apparatus described herein. The treated platelets can then be used to treat patients suffering from a thrombus blocking a blood vessel. The present invention is also related to a preparation of red blood cells that has a stable right shift of the oxygen dissociation curve.Type: GrantFiled: November 8, 2000Date of Patent: August 10, 2004Assignee: Maxcyte, Inc.Inventors: John W. Holaday, Peter H. Meserol, Doug Doerfler, Shawn J. Green, Vininder Singh
-
Publication number: 20040115784Abstract: Techniques for streaming electroporation. A representative but non-limiting method includes: generating a spatially inhomogeneous electric field with a pair of electrodes and displacing the pair of electrodes and a sample relative to one other while the electric field is substantially constant in terms of magnitude so that the sample is displaced across electric field lines for a time sufficient to effect electroporation.Type: ApplicationFiled: September 30, 2003Publication date: June 17, 2004Applicant: Maxcyte, Inc.Inventor: Sergey Dzekunov